Table 1.

Demographic characteristics of the patients

Patients (n)	43
Median age (year)	61 (51–72)
Median PSA level (ng/mL)	5 (2.7–9)
Patients requiring definitive treatment as determined by early re-biopsy, n (%)	22 (34%)
Tumor positive patients on active surveillance detected by re-biopsies, n (%)	9 (21%)
Patients on definitive treatment, n, (%)	9 (21%)
Median follow-up period (months)	50 (24–117)
Median follow-up period (months)	42 (24–117)
Patient lost to follow-up n, (%)	1 (2.3%)

PSA: prostate-specific antigen